AKT1 and colorectal cancer: Yang et al. [39] suggested that anlotinib suppressed cell proliferation and angiogenesis via inhibition of VEGFR-2/AKT and FGFR, PDGFRβ and their downstream signaling ERK in colorectal cancer.